Another anti-CD38 antibody, isatuximab, has also been tested in MM, NHL, and CLL patients in a phase 1 trial [108] and a phase 3 trial in patients with MM, which showed improvement in progression-free survival. Here, CD38 is linked to Miyoshi myopathy.